opinion
How PBM oversight could help lower drug prices
Pharmacy benefit managers are often blamed for driving up drug costs, but their role is much more complex than it appears. They help insurers and employers manage prescription benefits, and are able to negotiate lower drug prices through their formularies, write a trio of researchers studying this space.
The problem lies in the lack of transparency and the potential for misaligned incentives between PBMs and employers.
To keep PBMs in check, policymakers should focus on promoting competition and allowing for more flexible insurance designs that could lower drug prices and premiums.
Read more.
REGULATORY
FDA approves nasal auto-injector for anaphylaxis
On Friday, the FDA approved Neffy, the first needle-free nasal spray for severe allergic reactions. This is a much-needed alternative to epinephrine auto-injectors like the EpiPen. The spray, developed by ARS Pharmaceuticals, is meant to be easier, more affordable, and separate from the supply and design issues that have plagued existing treatments.
Neffy will likely cost $199 for a two-pack, with copays as low as $25 for insured patients. ARS is also exploring expanding the product's use for younger children, and also for other conditions like chronic hives and asthma.
Read more.
No comments